Prostate Cancer Then and Now: How New Approaches Have Changed Screening and Treatment

Prostate Cancer Then and Now: How New Approaches Have Changed Screening and Treatment
The Future of Medicine Podcast
Prostate Cancer Then and Now: How New Approaches Have Changed Screening and Treatment

Nov 16 2026 | 00:52:03

/
Episode • November 16, 2026 • 00:52:03

Show Notes

Chapters

  • (00:00:01) - Introduction and Guest Background
  • (00:01:47) - How Dr. Dainer Found Urology
  • (00:04:54) - Prostate Cancer Big Picture and Risk Factors
  • (00:08:25) - Shift from Aggressive Treatment to Surveillance
  • (00:10:45) - PSA Testing Pendulum and Modern Testing Approaches
  • (00:14:16) - Urine Biomarker Testing (Exosome/mRNA)
  • (00:16:31) - MRI and PI-RADS Scoring
  • (00:21:45) - Biopsy Procedure Explained
  • (00:23:10) - Gleason Score and Genetic Testing
  • (00:25:14) - Personalized Treatment Decisions
  • (00:29:18) - Treatment Protocols and Future of Gene Therapy
  • (00:33:31) - Questions Patients Should Ask and Treatment Options
  • (00:38:51) - Navigating Information Overload and Specialist Role
  • (00:40:08) - Germline Genetic Screening and BRCA
  • (00:43:04) - Testosterone and Prostate Cancer Relationship
  • (00:49:22) - Closing Thoughts and Patient-Centered Care
  • (00:50:58) - Podcast Outro and Resources
View Full Transcript

Episode Transcript

[00:00:01] Speaker A: Welcome to the Spotlight edition of the Future of Medicine podcast. I'm your host, Dr. Craig Wright. Join me as I have conversations with fascinating medical experts as we discuss a variety of compelling topics. We aim to not only inform you, but to empower you, instilling confidence along your journey toward optimal health. This podcast is brought to you by Brentwood, md. Located just south of Nashville, Tennessee, Brentwood, MD provides best in class concierge primary care. To learn more about our innovative approach to primary care, visit our [email protected] on this episode of the Spotlight Edition, I am joined by Dr. Ben Dainer, a leader in modern urology and surgical innovation here in Nashville. He completed his medical education and residency at the University of Cincinnati in 2010, and after nearly a decade of clinical work, he founded his own clinical practice, Nashville Urology, in 2021. As a board certified urologist, Dr. Dainer has contributed to research publications and medical education while also serving on several advisory boards. He displays a passionate commitment to advancing patient care and outcomes. We hope you enjoy our conversation. All right, thank you so much for joining me on this episode. Dr. Dainer, I'm really excited to speak with you. As we were just chatting off camera, I feel like some of the topics we'll get into are really pertinent to our practice here at Brentwood, md, but really just prevalent in the society, both male and female issues. And today we'll focus as we start on a male specific issue. But I do want to make sure we recognize that when a male is affected, the family is going to be affected. So hopefully we'll have a lot of value to this. [00:01:45] Speaker B: Absolutely. Thank you for having me. [00:01:47] Speaker A: Absolutely. Well, as we introduce you to our audience, I just want you to kind of tell us what led you into medicine and specifically into urology. [00:01:55] Speaker B: Yeah, so it's interesting. I wasn't planning to go to medicine. I was actually going to direct movies. Of all things. Like, it was like this passion of mine when I was [00:02:03] Speaker A: a [00:02:03] Speaker B: kid and it was growing up in the 80s with like Spielberg and all these things. And then as I started going down that path, I realized I was really awful at it. Of all things. Like, this was not at all what I should do with my time, but I really liked the other side of things like science and healthcare and stuff like that. And so it was kind of like a good entry point of going into college and then medical school to look at what really attracted me. So I studied biology. I have a psychology degree. And that really was kind of where I wanted to go clinically But I anticipated probably something more like neurosurgery when I started going into medical school. And I realized very quickly that I didn't have the temperament to be that kind of doctor. As you know, there are different kind of like ways that people kind of steer themselves. Like people go to orthopedics for certain reasons or cardiovascular, whatever it [00:02:56] Speaker A: is. Yeah. [00:02:57] Speaker B: And I was really surprised. And I got court kind of near the end of my medical school career and I still hadn't made a decision. I grew up playing a lot of video games. I'm definitely not the football player or anything like that. And I can play piano. I'm pretty good with my hands. And urology at that time was a field that was expanding and they had started this robot of all things that you could use to do surgery. And basically in where I was trained in Cincinnati, they were fortunate to have like one of the very first robots they had bought it for actually a cardiothoracic surgeon who never used it. So it was just sitting idle and the urologist started using it to do prostate cancer and some other things. And so I was very fortunate to get exposed to this kind of ahead of the curve. And to me it was just like an extension of like Call of Duty and PlayStation and everything else. I sat on my little console and I could just use my hands and feet and make things happen. [00:03:56] Speaker A: Wow. [00:03:56] Speaker B: So that really appealed to me. And then we do things like kidney stones and we have little instruments that we pass and little lasers and everything. And it was just like Star wars and stuff. You just drive your ship up there and you break it and pull it out. And so that was why I went to urology. I actually, the third year of my medical school, you did a one day rotation on a Saturday where you came in and you did a urologic course and you took an exam and you did a rectal exam on a patient. And I remember walking out at the end of that day being like, that's the last urology I'm ever going to do in my entire Life. And now, 21 years into this, it's still my day to day. [00:04:38] Speaker A: That's crazy. [00:04:38] Speaker B: Yeah, it was just. It's my kids, we all laugh about it because it's, you know, it's great to embarrass your children as a urologist when [00:04:46] Speaker A: they're of course [00:04:47] Speaker B: come over as teenagers. But it has definitely been a good decision for me. That's [00:04:53] Speaker A: great. [00:04:53] Speaker B: That's what I like to do. [00:04:54] Speaker A: That's kind of fascinating to think about because I know, during our conversation, we'll get into some of the advances and the technology around procedures and surgeries. And it's, it's, it's interesting to think that's part of what actually drove you into this field was some technology. Yeah, absolutely. That's pretty cool. Well, this episode we're really going to focus on prostate cancer. And like I was telling you off camera, I'm just really hopeful to get out of your way because I feel like prostate cancer, there is a lot of depth to it and a lot of complexity. But before we get into that, if someone is just thinking of kind of the current state of where prostate cancer is, what are some really just big picture themes that you want every man and his family to understand at this point? [00:05:39] Speaker B: Yeah. So one of the big things I think you have to understand is that prostate cancer is extremely common. I mean, there is going to be over 330,000 diagnoses this year. Of those diagnoses, you're going to get about 30,000 deaths with prostate cancer. So it's [00:05:58] Speaker A: a [00:05:59] Speaker B: tenth of the diagnoses are actually that concerning. But you have to look at it in that context. So just when someone comes to me and there's concern for prostate cancer, even if they've already had a diagnosis of the cancer, the first thing is to allay the fear to talk [00:06:17] Speaker A: to [00:06:18] Speaker B: the person, to talk to the family. Because usually, especially with my practice, most of the men are coming in with their spouse, their partner, you know, girlfriend, just a friend in general. [00:06:27] Speaker A: Yeah. [00:06:28] Speaker B: And that's the, the, the thing that we want to, you know, provide is that comfort of knowing that, yes, this may be your disease, but it doesn't define you. And also it doesn't change where you're going in life. You may never have to do anything about this. And we'll talk about that, or if we do have plans for it, these are the plans we're going to take. But at the end of the day, it is very unlikely. This is a disease that's going to change, change your quantity of life. We just have to decide how we're going to change the quality of it. [00:06:58] Speaker A: Yeah, that's a great, great insight and really good perspective out of the gate that immediately gives some, some sense of calm about the whole anxiety of, of do I have it or if I have it [00:07:09] Speaker B: right? [00:07:09] Speaker A: That's really helpful. What puts men at higher risk for developing prostate cancer? [00:07:15] Speaker B: So there's been a lot of look of this over the years and there's been question of diet, there's been question of medication. And it's still a lot of this is, is being studied, but usually there's like an ancestry to it. So if you're like of the black community, you tend to have a greater chance of having or developing prostate cancer. If you have like your father with prostate cancer, your brother with prostate cancer, those are conditions that would show a little bit more risk. Or if you're in a family where multiple people on the same family, like your father's side of the family has all these men with prostate cancer, that puts you at a little bit higher risk. One of the misconceptions is if like your mother's grandfather had prostate cancer, that you're more at risk or an uncle. If it's just like a one off like that, it does not increase your population or your risk at [00:08:09] Speaker A: all. [00:08:10] Speaker B: They've studied dietary things, so like high quantities of like red meat, things that are high in like, you know, hormones and things like that do have some association, but it's not a huge statistical risk. Surprisingly, smoking is not one of the risk factors for this disease. It tends to be really more an age thing. So the longer that you're on this planet, the more likely at some point that you may find prostate cancer. And I've seen studies that talk about like, you know, 90% of 90 year olds and 100% of 100 year olds, but it's not clinically significant and it's just there. And so the chances are that me, you, maybe the rest of us over time may have some of this, but the question then really becomes, does that really matter for you? And most of the time the answer may be no. And that's one of the things that changed over the course of my, my practice. Basically. [00:09:06] Speaker A: Yeah. [00:09:06] Speaker B: Because when I came and started urology in 2005, if you got diagnosed with prostate cancer, and we can talk about the Gleason score in a minute, but chances are we would have told you you needed to have your prostate removed. And the sooner you did it, the better. And [00:09:25] Speaker A: if [00:09:25] Speaker B: you didn't want it removed, you were getting radiation. And what has really changed now is more of a pivot away from all of that. And it's been more of a like almost like a hand tying effect to say, well, look, in this situation, me doing nothing is probably your best thing that I can do for you. And that takes a mindset. [00:09:45] Speaker A: Yeah. [00:09:46] Speaker B: And you and I have talked before about kind of talking with patients and communicating with them and like allaying their fears. And that's one of the things that you have to shift in their brain, which is, yes, you have now been told you have cancer. And you can see it the moment you tell somebody that their brain, there's like a switch. But then you have to then say, well, look, though, this isn't going to be a big deal. We're going to get you through this. We're [00:10:10] Speaker A: going [00:10:10] Speaker B: to walk you through this. And that's been one of the big pushes with urology over the last decade and a half, is to bring more men toward what we call surveillance rather than active treatment in the [00:10:23] Speaker A: right [00:10:23] Speaker B: patient. [00:10:24] Speaker A: Yeah. [00:10:24] Speaker B: And even at that, we get patients who push back. And at the end of the day, it's the patient's decision whether they want something treated or not, or how you approach it. But there's been a much grander push on kind of holding back and following rather than jumping the gun like we used to, Frank. [00:10:43] Speaker A: Yeah, well. And that echoes even my experience. When I finished my training out of medical school, I GUESS it was 2010. You know, it seemed to be at that time that, you know, an elevated PSA level got you a biopsy almost immediately, got you possibly major surgery. And then the pendulum kind of swung toward, oh, prostate cancer. You're probably going to die with it, not from it. [00:11:07] Speaker B: And [00:11:08] Speaker A: there was almost this nonchalance about it. [00:11:10] Speaker B: Right. [00:11:10] Speaker A: Where even the rectal exams and the PSAs kind of fell off some society guidelines. [00:11:16] Speaker B: Right. [00:11:16] Speaker A: And so it's like, well, this approach wasn't correct, this one's probably not correct. And it finds. It seems like we're finding a middle ground. [00:11:23] Speaker B: We really [00:11:24] Speaker A: are really thoughtful. [00:11:25] Speaker B: Exactly. Because what you're describing around 2010, 2011, 2012, was the U.S. preventative Task Force released a statement saying that you should not be doing PSA at all. They were very stark on this distinction. And from the 90s up until that time, it had focused so heavily on PSA, and if your PSA was above 4 to what you just said, biopsy, diagnosis, treatment. But then it swung the other way, and there was a time for a few years where there was very little PSA being done, know, in statistical comparison to where you were before. [00:12:04] Speaker A: Yeah. [00:12:05] Speaker B: And then we started seeing patients presenting with metastatic cancer or highly advanced or locally advanced disease, which is terrible. And you obviously, you know, there's gotta be some middle ground here. And so, like, for. With what I've seen with some of your patients and very vast majority of the ones that I see now, my first instinct is not to say, yes, let's jump to a biopsy. You really need to look at some other markers first. So we send off like urine testing that looks at MRNA in the urine now [00:12:39] Speaker A: and [00:12:40] Speaker B: that gets you a statistical analysis to say, well, look, yes, you have like a little bit more risk here, you have a lot more risk here. And a biopsy makes sense. [00:12:51] Speaker A: Yeah [00:12:51] Speaker B: or no, this is a very low risk situation, can be followed without doing anything and spare somebody the process of a biopsy or treatment or what have you. I think, and I think this applies a lot to most of medicine, as you know, in your practice. But I think it's a lot more personification and personalization of the care from the doctor to the patient. And you have to read kind of their input, which is if they're a high stress individual who really wants to know, then at some point you're probably going to get a biopsy. But if you can tailor it to give them the information and let them make a shared decision, that's a better approach. And fortunately, I mean, technology has come a long way. We've got more clinical markers, we've got more tests, imaging has come a long way. Mri, as far as an evaluation prior to a biopsy has [00:13:51] Speaker A: become [00:13:51] Speaker B: more and more of a standard in this industry, is not used in every patient. Because if you have a high PSA and you've got another test that shows that you've got a problem, you're going to probably end up in a biopsy anyway. And if [00:14:04] Speaker A: an [00:14:04] Speaker B: MRI shows nothing, it doesn't change that guidance. But if you can see a lesion on an MRI that gives you an area to target and it increases the value of going through that experience. [00:14:16] Speaker A: Yeah, yeah. Well, you just touched on something I was really interested in, which is kind of like, well, after, after an elevated or concerning psa, what's the next step? And so you mentioned some urine testing. Tell me a little bit more about what that looks like and how available that is and, and what the monitoring around that might be as far as the cadence and frequency of when that might be tested. [00:14:39] Speaker B: Yeah. So most of the time, at least in my practice, I always find that giving a little bit more information is better than not. You know what [00:14:49] Speaker A: I [00:14:49] Speaker B: mean? So it gives the patient more ability to decide what's really right for them. That, so the, the best kind of nuance to that is if in an area where the PSA is above 4, maybe less than 10 or 20, because when you start getting really high PSAs, like for example, I had a patient last week come to me brand new, never seen a urologist before. PSA was 55. The answer on that one is you're going to get that biopsy for sure. Because now my suspicion is very high. And including last year, I had a patient come and see me out of the box. PSA was a thousand. I mean, just way high. We knew there was already going to be bad things. There's no point going through a bunch of other tests. [00:15:30] Speaker A: But [00:15:30] Speaker B: if you're in that middle range where, like, there could be other reasons for that PSA being high, you know, your prostate getting larger, bph, prostatitis, a lot of times we see, like, men who cycle or active weightlifting and stuff like that where they're straddling. Those are the kind of conditions where we say, well, look, maybe getting a little bit more information is very easy. [00:15:53] Speaker A: Yeah. [00:15:54] Speaker B: For example, the MRNA test that we use called Exosome. I very regularly recommend that test because most of the people that come to see us have a PSA that's a little elevated, maybe slightly more than average. Do we need to rush, as we just talked about everybody, to greater cost of MRI or biopsy risk? No, it's a fairly inexpensive test. It runs about 100, 150 doll, and it usually buys peace of mind. And if it shows an abnormality, then that also provides peace of mind to the patient to say, well, look, you know, Dr. Wright sent me to see you. My PSA was elevated. Now I see this as potentially elevated. Now my mindset is, okay, let's really get to the root source of this rather than it being, okay, PSA is elevated, you know, wrote, you know, exactly the same thing every single time. Time. [00:16:45] Speaker A: Yeah, absolutely. Tell me a bit of how you approach imaging when that's appropriate and even maybe not in granular detail, but a little bit about kind of the grading of abnormal lesions within, like a PIRAD score, MRI and what that might mean and how you interpret some of those results on a obviously broad scale. [00:17:06] Speaker B: Yeah, yeah, I get you. So I like MRI in a couple conditions. One is if you're looking for a specific targetable lesion, that's a great place for MRI. Do I think that every patient in 2026, before going to a biopsy, needs an MRI? No. There's a cost to this, and there's only, you know, so much healthcare dollar that's available. [00:17:31] Speaker A: Yeah, [00:17:31] Speaker B: I don't think every single patient needs it. I do think, and this is the way I presented the patients, that if it would change a decision point for the patient or myself, then it makes a lot of sense. So, for example, if you're wavering on a PSA that's elevated and for example, an MRNA test that shows a possible concern, but maybe not a high, high definition of one, then I think an mri. Think an MRI makes a lot of sense. Because if you're going to say, well look, based upon an MRI, which can statistically miss up to 50% of what's there, it will not detect a low grade cancer. It tends to pick up more intermediate or more advanced cancer. [00:18:15] Speaker A: Yeah. [00:18:16] Speaker B: So if you would say that based upon this, if it doesn't show anything, I still wouldn't do a biopsy knowing that situation, then an MRI makes a lot of sense. If you would say, well look, I'm still going to go to that biopsy anyway. Does it universally make sense to get an mri? Probably not. [00:18:37] Speaker A: Yeah. [00:18:37] Speaker B: I also use it for patient follow up. So just because you have a high PSA once and we run a test and we say, well look, collectively we feel the risk here is low. That doesn't mean that in six months or a year or two years from now that this is going to be a static situation. Your body changes, your health changes of course over time. So we can use MRIs as a way of rechecking where we are. Okay. [00:19:02] Speaker A: If [00:19:02] Speaker B: that PSA rose slightly again further, do we want to check and see if we see something and if so, what does that mean? [00:19:09] Speaker A: Gotcha. [00:19:09] Speaker B: So mri, they graded on a what's called pyrad scale, as you mentioned. It goes from one to five. One and two are nothing. That's just normal prostate or bph, which is normal, benign growth. Then you get into what I kind of talk about like the three bears, three, four and five. So pyrad three is a lower risk but nonetheless targetable potential lesion. [00:19:32] Speaker A: Yeah. [00:19:33] Speaker B: Than four. And then five, five gets up to about 80% possibility of cancer. It's never 100%. And that's the thing you have to understand about MRIs is it can pick up prostatitis, it can pick up other lesions, hemorrhage that can look statistically abnormal, but it's not cancer. But that's where we kind of use that grading system to allay to a patient about this is what we feel like is going on here. This is what your statistical risk may be. What would you prefer to know? [00:20:03] Speaker A: Gotcha. That's really helpful. So if I'm tracking with you correctly there, you know, PSA maybe between a 4 to 10, you would go then toward the urine testing and allow that to guide. But if you have maybe a PSA in the 9 or 10 range with a elevated or abnormal signal from the urine test, you likely would be thinking maybe biopsy anyway. So a negative MRI wouldn't change the management. [00:20:32] Speaker B: Correct. Because [00:20:33] Speaker A: if [00:20:33] Speaker B: it's not going to really change what you're going [00:20:36] Speaker A: to [00:20:36] Speaker B: do anyway, unless you really need to target something. And this is all in flux because the way we typically do a prostate biopsy is an in office, very quick procedure, takes five minutes. In my practice, we usually use nitrous oxide. So patients are sedated slightly and they feel more comfortable and calm. And then it's over and very quick. What's called fusion biopsy is where you use an MRI with a specific type of guidance on an onlay on a computer to specifically hit a lesion that requires typically anesthetics. Now you've added in anesthesia and an operating room cost and all of these things to this. So it increases the time, increases the cost for the patient. I think there is going to be continued movement in that direction, but it's not universally the case right now for all biopsies. But you can use an MRI to do what's called cognitive guidance, which is where. Okay, I know this is the right side of the prostate in this area. I see a lesion. Let's be sure that we target that through my ultrasound and make sure we're getting samples from that area. [00:21:45] Speaker A: Gotcha. Well. And walk me through that kind of process of a biopsy. So like for in your office, when you suggest a biopsy biopsy, what should a gentleman expect? And, and what are you actually doing during that procedure, including what kind of, what kind of portion of the prostate are you looking at? How many samples might you get? Sure. And what are kind of the next step of interpretation from even a biopsy result? [00:22:10] Speaker B: It's a good question. So. So most standard biopsies now are still transrectal. So what that means is when, at least in my practice, what we do is we have a pre prep the patients do the day or the day of, we typically have them come in on Valium. So we like you to have a driver and then again the nitrous. And that combination usually makes things much more calm and comfortable. We have you lay down, we use an ultrasound to look through your backside, we numb you with a couple little shots and then we take out usually about 12 samples. The prostate is kind of like a heart. There's two sides to it, an apex, minute and a base. So you really are taking at least two specimens from each area. If you know there's a lesion, or if you've targeted something, you may take more samples. Takes about 5 minutes. Typically. Usually there's some blood in the stool, urine, and semen for a few days afterwards. There is an antibiotic on board. Because there is, of course, a small risk of infection. What we typically then do is at that point, you go home, you relax. We usually have you come back a week or two later to go over the pathology because the pathologists have to take their time, of course. Course, to go through the slides. What they're looking for is what's called a Gleason score. So Gleason is a term. Was a pathologist back in the day. And they're grading that on a scale from 6 to 10. So they say 6 is kind of like the baby of the prostate cancer. Seven's kind of the middle or intermediate. [00:23:38] Speaker A: And [00:23:38] Speaker B: then the eight, nine, and ten is the really nasty stuff. And that's the stuff that's really, really concerning. [00:23:43] Speaker A: Gotcha, gotcha. Tell me more about that. So, like, when you get that result back from a biopsy report, if somebody sees kind of one of those three zones of score, like the 6, 7, and then 8 or above, how are you counseling them about what could be next for them in terms of that man, like you were saying before, you know, maybe there will be intervention, maybe there will be active surveillance. Where does that kind of fall after that Gleason score in the biopsy comes in? [00:24:10] Speaker B: It's a good question. So usually let's. Let's take a step back. So back again to 2005, even back even closer to 2010. If the Gleason was found at all, even the 6, it was pretty much a standard response of, okay, you're going to have surgery, you're going to have radiation, whatever it is, These are the risk. What do you want to do now? What I do? So we already have set up with the puppy, but with the pathologist, there is genetic testing that's automatically sent on the tissue we set. That gets me more statistical analysis about what your risk of progression, what's your risk of metastasis to the future. That's automatically sent from all the pathology. We also send a different test if you come back benign, which is always a, you know, the hope. But what that test does is it looks in the area of where we sampled. Are there any markers that may be concerning for either cancer that was missed or cancer that may be developing to the future? So on both ends of the spectrum, we're sending genetic tests right away. [00:25:13] Speaker A: Great. [00:25:14] Speaker B: So when you come back to me and we say, look, I picked up Gleason 6 or Gleason 7 or the worst case scenarios. Now we also are saying to you, look based upon the number of samples that we pick up, the quantity of the specimen. So like if you have just one little spot of seven, but most of this is the less aggressive six, we may personalize that and say, well, look, based upon you, your psa, your age, your health, the genetics that we're picking up, that you're a great candidate for surveillance. Conversely, that same person with the seven who has genetic sampling that shows higher risk of progression, more cores that come back positive, any of those things, we may then sway in a different direction. It used to be very common even in that situation to recommend surgery. I feel like we're doing that as a community less and less, even as good as the technology has become, because of these personalizations, which is then you can take into account, you know, what is your risk of the future, what is your long term goal with your health. [00:26:28] Speaker A: Yeah. [00:26:29] Speaker B: And is surgery really the best step for you? And again, I'm a surgeon. That's, that's how I pay for Christmas in this situation. It's, it's really helpful and it's nice to be able to have a conversation with the patient to say, well, look, if I was sitting on that side of the table, I may do nothing, or I may do radiation where we just [00:26:49] Speaker A: don't [00:26:49] Speaker B: have to like aggressively remove prostates like we used to. And that's a huge shift in my community over the last 15, 20 years. [00:26:58] Speaker A: Definitely. [00:26:59] Speaker B: Yeah. [00:26:59] Speaker A: So now is there a correlation between the concerning genetics and the concerning Gleason, or are those kind of independent results there? I guess another way to ask that would be do you ever see a Gleason 6 on the lower side have really concerning genetics and vice versa, do you see some of the higher gleasons with more reassuring genetics? [00:27:21] Speaker B: We do. Although I would say when you start getting up into the really higher, like the Gleason nines, Gleason tens, and in those situations we can find it like multiple cores. So like if you come in and you have like a Gleason 7, but there's like 10 of my 12 cores positive. That may be much more concerning from a discussion standpoint, sometimes even than like a one core Gleason eight, or you know, a large core volume of six, you kind of have to look at the whole picture and then the genetics play into it because it gives you an ability to estimate future progression, future metastasis. And then obviously future death. The big thing with prostate cancer is it's like ovarian cancer, cancer. Like the historical history of this was that you didn't know you had it until it was very aggressive, like a T3, a T4 lesion that's in the rectum already, or metastatic or lymph node positive most of the time. Now, because of the usage of PSA imaging biomarkers, this has been found much earlier and we're avoiding those kind of lethal situations. And again, that's where I continue to say about the personalization. Then you have to take into account what is the best thing for the patient [00:28:43] Speaker A: from [00:28:43] Speaker B: their standpoint, which is, you know, from a surgical perspective, a radiation perspective. There are risks, trouble with erections, trouble with incontinence, bleeding, let alone downtime, the medical cost of it. And then the burden, not just on the patient, but on the family who's supporting this, Getting you through a surgery, getting you through multiple courses of radiation. That's why you have to take this whole pattern into account and really kind of decide what's the best discussion point with the patient. But the ultimate end of the day, of course, it's always their decision. [00:29:17] Speaker A: Yeah. Are there pretty standard protocols when you get into this space of like Gleason plus genetics? Are there, Is there pretty much like a playbook for what to do next? Or is this a situation where you speak to you on one day and another urologist on on another, they may have vastly different opinions. [00:29:36] Speaker B: Well, I mean, as you know as well as I, doctors are human and we all come with our own biases. I mean, if you are a very biased surgeon, you are probably going to be leaning more towards surgery than say, monitoring or radiation. And conversely, a radiation oncologist may feel more strongly about radiation than surgery. I do feel like in my practice and with the people that I refer with, [00:30:05] Speaker A: the [00:30:05] Speaker B: radiation oncologists that I like and use, they're very well trained. I think a lot of the biases have kind of gone by the wayside with some of this, but there is that kind of underlying kind of pattern with it. I do think that usually as you get into the higher grades, the gleasons, eights, the nines, usually the standard is surgery is your first and primary starting point. Because if you think of it like in a way of, like a one way street, usually the step first is surgery. But you may have to go like a multimodal approach where after surgery you still may need a treatment of radiation, you still may need hormones, you still May need to consider advances. [00:30:47] Speaker A: Yeah. [00:30:48] Speaker B: But the advantage in something like prostate cancer, cancer, much, much like breast cancer, is that there's been a wealth of research into this and a wealth of money spent on developing products upon products upon products, be it surgical technology, be it things that are outside of surgery right now that they're developing, like HiFu, which is ultrasound destruction of the prostate. [00:31:11] Speaker A: Yeah. [00:31:11] Speaker B: Be it laser ablation of the prostate, which are still kind of experimental or less standard, be it the armamentarium we have of hormones now, or as you get into the future, like PAR inhibitors and things like that that are based upon your genetics, maybe your germline mutations that you can have as an individual or a family, that is the next step. My oldest son, as we were talking about slightly earlier, is in college. He's studying molecular biology. He's thinking he wants to get into genetics as a field. And when I was in medical school, I don't know anybody that was like, specializing in genetics as a clinical application. [00:31:53] Speaker A: But [00:31:53] Speaker B: I think that's where this is going in the long term. Because if you look at, like the CRISPR technology, if you look at what was done here just the other month. Yeah, last month, that they were a study that they had done where they had done gene manipulation for certain forms of deafness, they were able to up to 90% regain function of their auditory canal. And people who were born deaf now could hear by gene manipulation. So if you think of the extraction of that, and I tell my son and my other son and my daughter about this all the time, that I think at some point you're going to look back at me as a surgeon. And the amount of surgery that we had used to do is almost barbaric. Like, the way we look back at, like the Middle Ages and stuff, and blood draws and leeches and all that crazy stuff. I think you're going to look back at this and be like, okay, why would I ever have removed a prostate if all I had to do is inject you with a plasmid that suddenly reversed all your cancer instantly? I mean, isn't that amazing? And I think that's where this is going, of course, over [00:33:02] Speaker A: time. Yeah. [00:33:03] Speaker B: We're just not to that point yet. [00:33:05] Speaker A: But [00:33:06] Speaker B: that's why we still have surgery, because there are those patients who still need that, and we still have radiation as a backup or as an alternative. But I think what we're finding is, is the longevity of the population increases. We're going to find that, hey, we really don't have a lot of patients who are having to jump things right away. And if we can delay that long enough, then the. The advances are coming, and they're coming faster and faster with AI and other things that will change, not just the patient practice, but the. The practice as a urologist, as a primary physician and how we manage these things. [00:33:46] Speaker A: Yeah. When you mentioned a few seconds ago about the surgical procedures. And so as you said that, I was kind of thinking, you know, if I were a gentleman walking into your office and I'd done some research, hopped online, looked at, okay, I got a. I'm really concerned I have prostate cancer. And then, you know, you start talking to your friends, you start looking online, and you see all these options. How. What kind of questions should men ask at their first urology appointment? Like, let's say that they're in there and they know they have prostate cancer and they're there to discuss next steps of treatment. [00:34:22] Speaker B: Right. [00:34:23] Speaker A: You know, a good example would be like, well, hifu like you mentioned versus maybe a total prostatectomy. What are some of the delineating facts that they need to make sure they understand and the questions they need to ask so that they can feel confident that what's being recommended to them is the best? [00:34:40] Speaker B: And I think some of that plays into the situation. So, for example, like a high grade, like Gleason 8, 9, 10, maybe potentially more advanced, depending on what the imaging shows. Those are the situations where you really have to think long and hard about what's the best bang for the buck. And again, that's where like surgery comes into play. Because by removing that large tumor burden, radiation potentially is still needed. It may not. [00:35:10] Speaker A: Yeah. [00:35:10] Speaker B: Removing lymph nodes is at is advantageous. The only way to do that is surgery. But it gets you a diagnostic result which is, was there positive lymph node or not? Was it a disease starting to spread? Was it outside of the capsule of the prostate? That's where surgery really comes into play. The. The gold standards that you see out there, surgery, radiation, and I'll include proton and radiation with this really have been the fundamentals of cancer treatment for years, Be it prostate cancer, breast cancer, [00:35:44] Speaker A: you [00:35:44] Speaker B: know, whatever it is that has been proven to work, of course, with advancing technology, hifu, the ultrasound, laser ablation. There is thought that that would maybe beneficial. I used to do cryotherapy a lot, which was where we froze parts of the prostate to kill tumor burden and it worked. But going back to the reasons that that exists is because we were looking for ways of treating prostate cancer with lesser and less of invasive Techniques to [00:36:15] Speaker A: try [00:36:15] Speaker B: to avoid some of the complications of surgery, be it again or erectile dysfunction, be it incontinence, be it downtime from, you know, work. [00:36:24] Speaker A: And [00:36:25] Speaker B: you have to really then look at what is the risk of my disease affecting me over time. Because you could do hifu on a Gleason 6 cancer, which is where a lot of that was being done and has been done. But then you actually look at the genetics of that low grade disease and if that disease realistically wasn't going to affect your quantity of life, maybe even your quality of life, did the hifu actually do you any good? And the answer is probably no. Because if it wasn't going to change the outcome here for you and you put yourself through a procedure, is that really beneficial? These techniques are not as well founded as some of the more standards. That doesn't necessarily mean they won't show that way over time, but we don't have 30 year data to show what is the long term risk of this. And there are side effects to these techniques. Aches, urethral strictures, bleeding, discomfort that can result and we don't know again how long that's going to be beneficial. So I think it requires the right patient. The nice thing in medicine, which is a double edged sword as you know, is that there's a wealth of information now available to patients that wasn't there 20 years ago. And you can google or chat or do whatever you want to do and put all of your information in and it's going to spit you back an algorithm. Whether all of that algorithm is correct depends upon the source of where that's coming from. And that's where I think as a urologist, as a physician, the point of this is to let the patient come in with that knowledge to say, look, I googled my disease and this is what I found. But then they have to have a step back and then let someone who has expertise in that kind of give them a guiding course or a hand or road to follow if [00:38:22] Speaker A: you think [00:38:22] Speaker B: of it like that, but then let them kind of express their fear or what their concern is. And so why are you latching on to the idea of doing laser ablation of your prostate, which has not been proven to be very beneficial, it's because they're afraid of the cancer. Well, can we either figure out is that cancer really going to be burdensome for you or is it that, yes, it's something that we need to manage, but we need to manage it the right way [00:38:50] Speaker A: and [00:38:51] Speaker B: get rid of it rather than mucking around. [00:38:53] Speaker A: Yeah. Wow. I have a saying that I share with my patients often and around the office that, you know, as a primary care doc, when I refer to specialists, I want them to do special things. And Even just the 10,000 foot view that you've given me on prostate cancer, this is complex. [00:39:13] Speaker B: It is, [00:39:14] Speaker A: you know, and it's a special thing and I'm glad that I'm not the one having to go through all of these thoughtful processes. I'm glad to have people like you I can refer to that can take, you know, maybe a positive screen or a concern or something and take it all the way to the goal line, so to speak. Because there's, with technology, it's so beautiful, but it doesn't necessarily make anything necessarily more simple. [00:39:37] Speaker B: Correct. [00:39:37] Speaker A: That it may just add other, other streets to the algorithm where you can actually maybe fine tune certain levels that get you further away from the treatment that you may have feared before. [00:39:52] Speaker B: Right. [00:39:52] Speaker A: But you can have confidence that, hey, we've got some great data here that say this is going to be a slow growing, fairly harmless cancer and then the risk of treatment for that would outweigh the benefits and, [00:40:06] Speaker B: and [00:40:06] Speaker A: vice versa. So [00:40:08] Speaker B: wow, fascinating. It's very fascinating where things are coming with this as well. And, and I think you're going to feel a lot of this to the future as well, even potentially more so than I, which is like that genetic pattern, that genetic screening. I mean, so if like you have an individual who's diagnosed young, let's say like in your 50s, or if they have a strong family history of disease or they show up and they already have node positive disease or high grade disease, now the push is to do, you know, germline screening. And that's very simple. I mean it can be salivary, it can be blood, but this is a way of then looking for. Are you BRCA2? Are you BRCA1? [00:40:52] Speaker A: Yeah. [00:40:53] Speaker B: You know, do you have any of like the ATM mutations like Lish Niman syndrome? Because there are ways then of then doing targeted therapy which I think is going to continue and become more and more the standard of your disease directly for you. So if like you're BRCA2 positive, you have a much higher risk of prostate cancer even if you don't have cancer now. [00:41:17] Speaker A: Yeah. [00:41:17] Speaker B: So if your father was diagnosed, John, and then you test positive for BRCA, let's say you're 38, I would push that. You should probably start getting PSAs at 40 regularly. And if you are bracket negative and you didn't have this, we may Be talking a shared decision point at 50. That's coming from you as [00:41:38] Speaker A: the [00:41:38] Speaker B: primary. Because you're going to be having this conversation because by the time they've already seen me, you've already PSA screened them. So I think there's going to be this downward trend of things that we're doing as urologists that now becoming more and more the standard baseline. And you're going to be the frontline source. Yes. [00:41:57] Speaker A: When that's interesting, too. And I want to make sure, as you were going down that path, that. That I'm correct in how I think about the genetics, where we've talked a bit about genetics there. And you have kind of your personal genetics, like your BRCA2 and such, but then you have the cancer genetics, and those are different. Correct. [00:42:17] Speaker B: Yeah. So there are conditions that are heritable. [00:42:20] Speaker A: Yeah. And [00:42:20] Speaker B: that's what I'm referring to as far as like your BRCA situation. [00:42:24] Speaker A: Yes. Like [00:42:25] Speaker B: the Ashkenazi Jewish population has a much higher risk versus genetic mutations with the cancer itself. [00:42:33] Speaker A: Yeah. Which [00:42:34] Speaker B: then increase or decrease responsiveness, targeted therapies, those sorts of things. And there's a distinction here. And that's kind of what I was saying as we were talking about that initial biopsy. [00:42:45] Speaker A: Yeah. [00:42:45] Speaker B: That even if you're a benign biopsy, we are still looking for other things through the testing that's available to us. And I think that's becoming much more, not just the standard, as I was saying, but I think it's also going to expand into more and more fields and more and more medical care in general, because it's that personalization. I mean, you do a great job with your patients of personalizing your care and spending time with them. And I think this is going to be one more adjunct to [00:43:12] Speaker A: this. [00:43:13] Speaker B: So, for example, if you talk about like, testosterone and prostate cancer, which has been a huge hot topic for years, it used to be felt that testosterone caused prostate cancer. That was what I was taught in medical school and residency. [00:43:28] Speaker A: Yeah. [00:43:29] Speaker B: And the data actually shows it's not that way, that testosterone is not causing prostate cancer. It can unmask something that may already be present. It can accelerate what's potentially there. And so we see patients coming from, you know, primary clinics, we see people from, like, the low testosterone centers who are on testosterone. And what can unmask at an earlier stage is potentially a tumor that was not going to be clinically viable for another decade start to unmask itself. The youngest patient I ever had a prostatectomy on was 36, and he had a rapid PSA shift over the course of a two year time on testosterone. And when he presented, he had nasty cancer, but it was because of the fact that he probably genetically was already predisposed [00:44:25] Speaker A: and [00:44:25] Speaker B: we didn't have the ability then to check. But I think what will happen to the future is for like those patients that are coming in and discussing with you about their testosterone symptoms, their fatigue, their libido, I think what we'll eventually see is that you're going to not just do a blood check for testosterone and see what it is, but I think you're also going to do some testing to see what is their progressive risk of cancer over time. And is testosterone the right option for you at this point? Again, it's like a shared decision plan. [00:44:59] Speaker A: Yeah. So does testosterone feed, so to speak, every type of prostate cancer or is it only certain genetics within that prostate cancer where you see testosterone be the thing that maybe unmask that [00:45:14] Speaker B: we as urologists, and again this is very clinically still in flux right now, but it looks like the testosterone itself is not causing that event, that initial shift, shift of that tumor cell. But it does seem to accelerate what is there already. [00:45:34] Speaker A: Gotcha. [00:45:34] Speaker B: So and then there's this whole like hypothesis of our if you're a patient with prostate cancer that is untreated, let's go back to that Gleason 6 low risk individual, maybe they're 60, whatever that [00:45:51] Speaker A: is, [00:45:51] Speaker B: but they're having low testosterone, fatigue, libido changes. There's only so many receptors that that cancer [00:46:01] Speaker A: has [00:46:01] Speaker B: available to bind testosterone and it doesn't take a lot of testosterone. So there's a lot of study going on right now which is what is the minimum amount of testosterone it takes to bind all those receptors on the cancer. [00:46:16] Speaker A: And [00:46:16] Speaker B: therefore then is it safe or not for that patient on surveillance to remain on testosterone? [00:46:22] Speaker A: Yeah, [00:46:23] Speaker B: I personally feel like it is. Okay. Because the data shows that the castrate level of testosterone, which is around 50 and normal, would be like at least 300. If I'm giving you testosterone and your testosterone is 900, but it only takes 50 to saturate [00:46:42] Speaker A: the [00:46:42] Speaker B: cancer, does it matter if there's another 850, so to speak of testosterone? Probably [00:46:49] Speaker A: not, [00:46:49] Speaker B: but it's going [00:46:49] Speaker A: to [00:46:50] Speaker B: make you feel, feel better. [00:46:51] Speaker A: Yeah, [00:46:52] Speaker B: but you need to then be very cognizant of is that accelerating any cancer? So we definitely in those patients recommend PSA screening and then definite follow up over time to re biopsy at [00:47:06] Speaker A: this [00:47:06] Speaker B: stage. [00:47:06] Speaker A: Wow, that's a great topic there. And that's, you know, actually the, the one I kind of wanted to end this episode on was kind of talking through that role of, of testosterone and how it interplays with cancer. And I think that's a great way to end this part of the conversation because it's something that I love. And I think I agree with your viewpoint where you really look at the two entities separately, but recognizing how they can interplay and affect each other. And you don't want to just say, well, you have a low grade indolent prostate type cancer, let's avoid testosterone. Because it could be that their quality of life would be greatly impacted, affected by the testosterone. And you just want to be aware of, hey, here's where we are. It's not a no go, but we need to watch it, we need to be careful. And [00:47:57] Speaker B: I think hormones are very interesting. And obviously there's this whole industry that is blossoming between testosterone, testosterone replacement, estrogen replacement in women, testosterone replacement in women, and then all the GLP1s, of course, that you're probably more involved in than I at this point. But I think it's a huge industry that is blossoming because as we get older, we are less accepting as a population of just dealing with the consequences of age. And as men, as we're losing 1% of testosterone every year and women obviously have menopause and perimenopause and my wife is going through much of this as we speak. It's a miserable situation. And if you can reverse some of those symptoms to [00:48:46] Speaker A: give [00:48:46] Speaker B: that quality of life metric back safely. [00:48:50] Speaker A: Yeah, [00:48:51] Speaker B: that's, that's game changing. And why would you want to spend the next 30 years of your life miserable and tired and fatigued if you can avoid it? [00:48:58] Speaker A: It [00:48:59] Speaker B: just has to be done in the right way. [00:49:00] Speaker A: Yeah. [00:49:01] Speaker B: And so, you know, we'll see patients who, they had got testosterone. It's always on the Internet. It's always something that they found and everything like that. And they don't go monitor. That's where the danger is. Yeah. There's nothing wrong with trying to improve your quality of life. It just needs to be handled in the right way with the right guidance and the right safety net. [00:49:22] Speaker A: Yeah, perfect. Well, Dr. Dainer, as we wrap up this episode on prostate cancer, is there anything that I have not specifically asked about that you want to make sure our audience knows of? [00:49:34] Speaker B: I wouldn't say no. I mean, you, you do a great job with your patients and I, I appreciate this conversation with you and the time. I just, again, I always emphasize back to the idea that like the way that we're going in medicine, especially with cancer, has to be patient centered and it has to be based upon that person in that room at that point. And a lot of the fallacy I get with patients is they had this friend that had this treatment for their cancer and that's what they're supposed to. Supposed to do. [00:50:04] Speaker A: Yeah. [00:50:04] Speaker B: And they come in with that preemptive bias and you just have to allay that and say, well, look, your friend may have had a more high Gleason score, he may have had a psa, he may have had a PET scan that showed some problem. We need to focus on you and what do you need? [00:50:21] Speaker A: Yeah, that's a good, good insight going back to those special things you do is, you know, there is not a one size fits all. There's a lot of detail. And, you know, it's, it's good to have community. It's good to be able to share with friends and family and even to have some empowerment from Internet resource, Internet research. But it's really important to work with people like you who can kind of break it down and say, hey, this is actually where that research is applicable to you. [00:50:46] Speaker B: Yeah. [00:50:48] Speaker A: So, yeah. Thanks for your time in this conversation and all the care you provide. [00:50:52] Speaker B: I agree. This was awesome. Thank you. [00:50:54] Speaker A: Thanks. Thank you for listening to this conversation. I truly hope you found it useful. You can find out more about today's episode and discover additional [email protected] be sure to check out all of our other content that we've created by searching BrentWoodMD on LinkedIn, Facebook, YouTube and Instagram. If our content has provided you with value, it would mean the world to us if you subscribe to the show and left a review. This helps us ensure that more people just like you can find our content so that they can begin optimizing their health. To learn more about our concierge services that we provide to our members, visit brentwoodmd.com we'd love to meet you. This podcast was for general information only and does not constitute the practice of medicine or giving of medical advice as no doctor patient relationship has been formed. The the content of this podcast is not intended to substitute for professional medical advice, diagnosis or treatment. Listeners should seek the advice of their own trusted medical professional.

Other Episodes